The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
=== Cysteinyl leukotrienes === LTC4, LTD4, LTE4 and LTF4 are often called cysteinyl leukotrienes due to the presence of the amino acid cysteine in their structure. The cysteinyl leukotrienes make up the slow-reacting substance of anaphylaxis (SRS-A). LTF4, like LTD4, is a metabolite of LTC4, but, unlike LTD4, which lacks the glutamic residue of glutathione, LTF4 lacks the glycine residue of glutathione.
== Repair == L-isoaspartyl methyltransferase repairs isoaspartate and D-aspartate residues by sticking a methyl group onto the side chain carboxyl group in the residue, creating an ester. The ester rapidly and spontaneously turns into the succinimide (red), and randomly turns back into normal aspartic acid (black) or isoaspartate again (green) for another attempt.
==== Oceania ==== Slaves (he mōkai) had a recognised social role in traditional Māori society in New Zealand. Blackbirding occurred on islands in the Pacific Ocean and Australia, especially in the 19th century.
Sources: en.wikipedia.org
== Partnerships == Towards fulfilling its mandate, RCB is collaborating with various national and international institutions of repute. The partnerships are meant for exchange of ideas, information sharing, training, networking, conducting scientific colloquia, workshops, academic exchange programmes and student study visits within (and outside) India and for students of the Asia-Pacific region. RCB and National Institute of Advanced Industrial Science and Technology (AIST), Japan announced a partnership to further capacity building initiatives in bio-imaging and biotechnology. The agreement offers an excellent opportunity for both the institutions in capacity building, training and research collaborations, benefitting young scientists not only in India and Japan, but also from the UNESCO member countries in the Asia-Pacific and SAARC regions. In its continuing effort to fulfill the core mandate, RCB is actively engaged in a range of research and related activities in partnership with other academic institutions, which form part of the NCR Biotech Science Cluster, Faridabad. Shared facilities such as Advanced Technology Platform Centre (ATPC), and Bioincubators (supported by Biotechnology Industry Research Assistance Council (BIRAC)), which is meant to support the budding biotechnology entrepreneurs, are being established.
A work of non-fiction Echoes of Life: What Fossil Molecules Reveal about Earth History, published in 2009, provides an up-to-date survey of the interdisciplinary field of organic geochemistry, using the history of discovery, from early experiments in the 1930s to modern areas of research, to make the material accessible to students and scientists in different fields.
Alexander McLeish. For services to Charity. Martin Gerard McTague. Low Pay Commissioner and National Chair, UK Federation of Small Businesses. For services to Small Businesses. Thomas Anthony Meadows. Lead Operations Manager, Security Services Group, Defence Infrastructure Organisation. For services to Defence. Dr. Teame Mebrahtu. For services to Education, to Refugees and to the community in Bristol. Dr. Nicholas John Merriman. Chief Executive, The Horniman Museum and Gardens. For services to the Arts and to Heritage. Gillian Jayne Millane. Co-Founder, Love Grace. For services to Charitable Fundraising and Tackling Violence Against Women. Dr. Jane Patricia Monckton-Smith. Professor of Public Protection, University of Gloucestershire. For services to Criminal Justice. Keith Morgan. Coach, Crystal Palace Weightlifting Club. For services to Sport. Andrew David Murphy. Lately Chief Operating Officer, John Lewis Partnership. For services to the British Retail Industry. Professor James Michael Olu N'Dow, DL. Professor of Urological Surgery, University of Aberdeen. For services to Cancer and Urology, and to Voluntary Work. Professor Kimberley Anne-Isola Nekaris. Head, Nocturnal Primate Research Group, Oxford Brookes University. For services to Conservation. Kenneth Paul Newton. Governing Governor, HM Prison Birmingham. For Public Service. Robert Stewart Nicol. Lately Chief Executive, Inverness Chambers of Commerce. For services to the Economy of the Highlands of Scotland. Beryce Amy Nixon. Chief Executive Officer, Exceed Learning Partnership Trust. For services to Education.
Sources: en.wikipedia.org
Anirudh Ravichander composed Darbar's soundtrack and score, marking his second collaboration with Rajinikanth after Petta (2019) and also with director A. R. Murugadoss after Kaththi (2014). "Thalaivar Theme", an instrumental theme for the film, was released on 7 November 2019 to accompany the motion poster. The film's first single "Chumma Kizhi", whose lyrics were written by Vivek and sung by S. P. Balasubrahmanyam, was released on 27 November 2019. The film's album was launched on 7 December 2019 at Jawaharlal Nehru Indoor Stadium, Chennai, in the presence of the film's cast and crew; it was made available to stream through the online streaming platform Gaana on the same day. The film's soundtrack has an unreleased hidden song titled "Kannula Thimiru", which was recorded by trans-woman singers Chandramukhi, Rachana and Priya Murthi, and was performed live at the film's audio launch. For the song, Anirudh engaged veteran composer Deva to conduct the song's brass section; a making-of video of the song was released in mid January 2020 and went viral on the internet. Sify stated "the soundtrack album is quite disappointing as compared to Rajinikanth's earlier film Petta, due to the unimpressive lyrics but it touches the listener's soul and enables them to sing along".
== History == Crocodile oil was used by traditional practitioners for centuries in treatment of ailments, skin conditions, and illnesses such as cancer. In Ancient Egyptian medicine, crocodile oil was used in a liniment to stimulate the growth of hair, to treat bald patches also called alopecia as well as prevent grey hair growth. Crocodile oil was recognised by the Ancient Egyptians to treat burns when combined with other components such as Egyptian goat fat and lion fat. Crocodile oil was also used by the Egyptians to help with trembling in limbs when smeared with other components including honey and olive oil. The Papyrus Ebers mentions Egyptians medicine recommends the creation of a vaginal contraceptive solution composed of crocodile oil, gum acacia or honey, and natron. The Historical Table of the Materia Media reports crocodile oil use in Egyptian Medicine in creating the ointment with combination of "slime of the nile", frictions of crocodile fat in rheumatism, salt, alum, platters. In Africa, crocodile oil is used for ailments such as skin rashes and to promote wound healing. There is also evidence of crocodile oil being used traditionally in South Africa. South Africans consult traditional healers, who still play a role in healthcare in rural areas. Crocodile fat is mixed with the ground bark of Cryptocarya latifolia and used by the Zulu people to treat chest ailments. Crocodile oil was also used by Indian Ayurveda medicine in the nineteenth century for treatment of burns.
One of the largest traditional markets in Taiwan, the Jianguo Market in Taichung, was torn down and replaced by a new facility in 2016. The new facilities provided better hygiene, disability accessibility, and refrigeration, but the relocation was initially met with hesitation from the local vendors before a grassroots outreach campaign led to greater acceptance.
==== History ==== All Sendai virus strains belong to the same serotype. The origin of many strains of SeV was described in 1978. Some strains such as Ohita and Hamamatsu were described later. Ohita and Hamanatsu strains were isolated from separate epidemics in laboratory mice. According to the personal memory of Alisa G. Bukrinskaya, who has co-authored numerous publications related to SeV along with Viktor M. Zhdanov, starting in 1961, the Moscow strain of SeV was obtained by Viktor M. Zhdanov of the Ivanovsky Institute of Virology from Japan in the late 1950s or early 1960s, It is reported that the BB1 strain derived from the Moscow virus strain. The strain BB1 was given to the researchers of Institute of Viral Disease Control and Prevention, Beijing, China by researchers of Ivanovsky Institute of Virology, Moscow, Russia in the 1960s.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.